ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2633

Multicenter Validation of a Machine Learning Foundation Model to Diagnose Sjögren’s Disease and Identify Histological Biomarkers for Disease Stratification

Julien Duquesne1, Charlotte Claye1, Louis Basseto1, Michael Barnes2, Elena Pontarini3, Amaya Syed2, Michele Bombardieri4, Benjamin A. Fisher5, SABA NAYAR5, Andreas Goules6, Athanasios Tzioufas7, Loukas chatzis8, Wan Fai Ng9, Bec Scane10, Matilde Bandeira11, Vasco C. Romão12, Thierry Lazure13, Clovis Adam14, Xavier Mariette15, Samuel Bitoun16 and Vincent Bouget17, and NECESSITY Consortium, 1Scienta Lab, Paris, France, 2William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, 3William Harvey Research Institute, London, United Kingdom, 4Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 5University of Birmingham, Birmingham, United Kingdom, 6GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, 7LAIKO HOSPITAL, Athens, Greece, 8Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, 9Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, 10Department of Rheumatology, Newcastle University, Athens, Greece, 11Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, 12Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 13APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, 14APHP. Université Paris-Saclay, Hôpital Bicêtre, Laboratoire de neuropathologie, Paris, France, 15Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 16Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 17Scienta Lab, Gif-sur-Yvette, France

Meeting: ACR Convergence 2024

Keywords: Bioinformatics, Diagnostic criteria, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Sjögren's Syndrome – Basic & Clinical Science

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Sjögren’s Disease (SjD) classification relies on the EULAR/ACR 2016 criteria: i) quantifying lymphocyte infiltration in labial salivary gland (LSG) biopsies, ii) autoantibody status and iii) objective quantification of eye and mouth dryness. Diagnosis is challenging due to heterogeneity of clinical manifestations and underlying biology, especially for seronegative patients, who comprise about 30% of the SjD population.

In a proof-of-concept study, we have demonstrated that a machine learning foundation model for histology achieved an area under the ROC curve (AUROC) of 84% in SjD diagnosis using digitalized LSG only [1]. As the main criticism towards AI are validation and mono-centricity bias, the study was extended to 6 centres. We also assessed the model’s performance in the difficult-to-diagnose seronegative population and leveraged the foundation model to identify histological biomarkers associated with SjD.

Methods: A deep learning foundation model was fine-tuned using digitalized LSG slides from 6 European expert centers of the NECESSITY consortium, a H2020 IMI2 project. Three patient groups were included: patients with sicca symptoms without autoantibodies and with FS< 1; SjD patients with FS ≥1; and SjD patients with FS< 1. All diagnoses were confirmed by expert rheumatologists and met the EULAR/ACR 2016 criteria.

The model was fine-tuned on 5 centers, the 6th center served as external validation. Algorithm performance was measured using AUROC, positive and negative predictive values (PPV and NPV), specificity and sensitivity. A subanalysis assessed model’s performance on SSA- patients.

A state-of-the-art machine learning technology – concept-based explainability – was used to flag histological patterns correlated to SjD diganosis.

Results: We included 545 patients – 436 patients in the training set and 109 in the validation, see Table 1. In the validation set, the model achieved an AUROC of 0.89 (95% CI 0.82 to 0.94) for SjD diagnosis – compared to 0.84 (95% CI 0.83 to 0.86) in the 2023 study with 3 centers. Notably, for the seronegative population, the model achieved an AUROC of 0.95 (95% CI 0.87 to 1) – this result is particularly interesting as seronegative patients are the hardest to diagnose. The performances are presented in Table 2.

In addition, histological patterns most associated with SjD were identified (Figure 1). As expected, lymphocyte aggregates were correlated with SjD (Tab A). Interestingly, the model also identified fibrosis (Tab B) and lympho-epithelial lesions (Tab C) as SjD markers. These histological patterns serve as potential histological biomarkers for stratifying SjD in homogeneous patient subgroups, supporting precision approaches in drug development and therapeutic approach.

Conclusion: This study is a large multicentric validation of a machine-learning foundation model for SjD diagnosis. Potential histological biomarkers were identified and could serve for SjD stratification, supporting precision therapeutic approaches.
1. Basseto L, et al. Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies. Arthritis Rheumatol. 2023.

Supporting image 1

Table 1: Presentation of the data sources and distribution between the training and validation sets.

Supporting image 2

Table 2: detailed performance results on the validation set of the models (PPV: positive predictive value, NPV: negative predictive value, mean confidence interval (CI)).

Supporting image 3

Figure 1: Histological patterns flagged as highly correlated to SjD by the model, including lymphocyte aggregates (Tab A), fibrosis (Tab B), and lympho-epithelial lesions (Tab C).


Disclosures: J. Duquesne: None; C. Claye: None; L. Basseto: None; M. Barnes: None; E. Pontarini: None; A. Syed: None; M. Bombardieri: None; B. Fisher: Bristol Myers Squibb, 2, Galápagos, 2, 12, Research funding, Janssen, 2, 12, Research funding, Novartis, 2, Roche, 2, Sanofi, 2, Servier Laboratories, 2, 12, Research funding, UCB, 2; S. NAYAR: None; A. Goules: AbbVie/Abbott, 6, Amgen, 1, Pfizer, 2; A. Tzioufas: Pfizer, 2; L. chatzis: Pfizer, 2; W. Ng: Amgen, 2, Argenx, 2, IQVIA, 2, Johnson and Johnson, 2, Novartis, 2, sanofi, 2; B. Scane: None; M. Bandeira: None; V. C. Romão: None; T. Lazure: None; C. Adam: None; X. Mariette: Bristol-Myers Squibb(BMS), 2, Galapagos, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2, Pfizer, 2; S. Bitoun: Alpha Sigma, 6; V. Bouget: None.

To cite this abstract in AMA style:

Duquesne J, Claye C, Basseto L, Barnes M, Pontarini E, Syed A, Bombardieri M, Fisher B, NAYAR S, Goules A, Tzioufas A, chatzis L, Ng W, Scane B, Bandeira M, C. Romão V, Lazure T, Adam C, Mariette X, Bitoun S, Bouget V. Multicenter Validation of a Machine Learning Foundation Model to Diagnose Sjögren’s Disease and Identify Histological Biomarkers for Disease Stratification [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/multicenter-validation-of-a-machine-learning-foundation-model-to-diagnose-sjogrens-disease-and-identify-histological-biomarkers-for-disease-stratification/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multicenter-validation-of-a-machine-learning-foundation-model-to-diagnose-sjogrens-disease-and-identify-histological-biomarkers-for-disease-stratification/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology